Market Overview

GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

Share:
GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoints.

On Monday morning, a number of firms have downgraded the stock:

  • Jefferies downgraded the stock from Buy to Hold.
  • SunTrust Robinson Humphrey downgraded from Buy to Hold and lowered the price target from $23 to $5.
  • Piper Jaffray downgraded from Overweight to Neutral and lowered the price target from $20 to $6.

GlycoMimetics shares were trading down 51.81% at $4.40 in Monday’s pre-market session. The stock has a 52-week high of $17.07 and a 52-week low of $8.29.

Related Links:

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

Posted-In: Rivipansel sickle cellNews Health Care Top Stories Movers Trading Ideas General Best of Benzinga

 

Related Articles (PFE + GLYC)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

10 Biggest Price Target Changes For Monday

Tesla To Offer Free Unlimited Supercharging